De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient

• DOI: 10.1111/ajt.13852
• Publication Date: 2016-05-03T12:32:11Z
• Authors: E.A. Cohen; D. Mulligan; S. Kulkarni; E.M. Tichy
• Keywords: Belatacept; Immunosuppression

Benefits of belatacept-based immunosuppressive regimens in human immunodeficiency virus (HIV)-positive renal transplant recipients include avoidance drug interactions between calcineurin inhibitors and highly active antiretroviral agents decreased likelihood or severity nonimmune toxicities such as new-onset diabetes after transplant, hyperlipidemia hypertension. We report a successful case de novo belatacept at >18 mo from an HIV-positive black man aged 50 years who received his first living related kidney donor. To our knowledge, this is the reported use recipient.